Following U.S. Stocks are among the “Top Losers” Stocks in the course of recent trading session, Friday: OHR Pharmaceutical Inc (NASDAQ:OHRP), Applied DNA Sciences Inc (NASDAQ:APDN), Quiksilver, Inc (NYSE:ZQK)

• OHR Pharmaceutical Inc (NASDAQ:OHRP), with shares dwindled -64.95% is now trading at $3.06, hitting new 52-week low of $2.90. The Stock is active as 11.99M shares changed hands versus its average volume of 492,320.00 shares.

• Applied DNA Sciences Inc (NASDAQ:APDN), with shares dipped -14.33% is now trading at $2.69. The Stock is active as 477,126.00 shares changed hands versus its average volume of 84,025.00 shares.

• Quiksilver, Inc (NYSE:ZQK) with shares dropped -13.78% is now trading at $1.94. The Stock is active as 1.52M shares changed hands versus its average volume of 1.96M shares.

Latest NEWS regarding these Stocks are depicted underneath:

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)

Today, Ohr Pharmaceutical, Inc. (OHRP), declared the topline results from the exploratory Phase II INFLUENCE study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). In the intent-to-treat (ITT-LOCF) population with classic containing choroidal neovascularization (CNV) (OHR-102 n=38, Lucentis(R) monotherapy n=32), 42% of the patients receiving OHR-102 achieved a >=3 line gain at nine months, as contrast to 28% in the Lucentis monotherapy group. Less of a benefit was seen in the overall population (classic containing and occult only CNV lesions). The classic containing CNV population represents about two thirds of the total wet-AMD population. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to raise through the end of the study, supporting the planned Phase III development program.

In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. The mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different. Detailed data will be presented at the forthcoming Association for Research in Vision and Ophthalmology (ARVO) scientific meeting, which will take place May 3rd — 7th.

Ohr Pharmaceutical, Inc. is an ophthalmology research and development corporation whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several corporation-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases comprise the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy.

Applied DNA Sciences Inc. (NASDAQ:APDN)

Today, Applied DNA Sciences Inc. (APDN), declared that it has priced its formerly declared underwritten public offering of 3,820,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 1,528,000shares of ordinary stock, at a combined public offering price of $3.00. The warrants have an exercise price of $3.50 per share, expire on November 20, 2019 and will trade under the symbol APDNW.

The gross proceeds to the Corporation from this offering are estimated to be about $11.46 million before deducting the underwriting discount and other estimated offering expenses. The Corporation has granted the underwriters a 45-day option to purchase an aggregate of up to 573,000 additional shares of ordinary stock and/or warrants to purchase up to 229,200 shares of ordinary stock to cover over-allotments, if any. The offering is predictable to close on or about April 1, 2015, subject to customary closing conditions.

The Corporation intends to use the net proceeds from this offering for general corporate purposes, counting working capital, capital expenditures, business development and research and development and attainments of new technologies or businesses.

Maxim Group LLC is acting as the sole book runner for the offering with The Benchmark Corporation acting as Co-Manager.

Applied DNA Sciences, Inc. provides botanical DNA-based technologies for supply chain security, brand protection, and law enforcement applications in the United States, Europe, and Asia.

Quiksilver Inc. (NYSE:ZQK)

Today, Quiksilver Inc. (ZQK), declared that Pierre Agnes, President of Quiksilver, Inc., has been promoted to Chief Executive Officer and added to the Board of Directors; he succeeds Andy Mooney who is no longer with the corporation. In addition, Greg Healy, Quiksilver’s APAC Region President, has been promoted to President of Quiksilver, Inc., and Bob McKnight has been designated Chairman. All changes are effective today.

Bob McKnight, Founder and Chairman of Quiksilver, Inc., said, “On behalf of the board, I want to thank Andy Mooney for his leadership in driving the organizational changes that were essential to restoring our product design leadership and globalizing many of our key functions. This work provides the foundation for the next phase of Quiksilver’s progress.

Quiksilver, Inc., one of the world’s leading outdoor sports lifestyle companies, designs, produces and distributes branded apparel, footwear and accessories. The Corporation’s apparel and footwear brands, inspired by a passion for outdoor action sports, represent a casual lifestyle for young-minded people who connect with its boardriding culture and heritage.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.